<DOC>
	<DOCNO>NCT00786513</DOCNO>
	<brief_summary>The purpose study determine whether choose antibiotic base biofilm antimicrobial susceptibility assay rather conventional planktonic antimicrobial susceptibility assay treat CF patient chronic P. aeruginosa infection acute pulmonary exacerbation safe intervention result improve microbiological clinical outcome decrease marker pulmonary inflammation .</brief_summary>
	<brief_title>Use Biofilm Antimicrobial Susceptibility Assay Guide Antibiotic Therapy</brief_title>
	<detailed_description>Cystic fibrosis ( CF ) common fatal genetic condition Caucasian population affect 3,000 Canadians . Respiratory failure cause chronic pulmonary infection primary cause death CF patient . The improved life expectancy CF patient past several decade due part aggressive use antibiotic treatment respiratory infection . However , currently antimicrobial susceptibility assay predict antibiotic result improve patient outcome . Since Pseudomonas aeruginosa know grow resistant biofilm CF lung , antimicrobial susceptibility test base biofilm growth P. aeruginosa may lead different antibiotic choice significantly decrease pulmonary bacterial density P. aeruginosa . A biofilm antimicrobial susceptibility assay thus ability change way antibiotic choose treat CF patient result improve lung function longer live CF patient .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Disease Susceptibility</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibiotics , Antitubercular</mesh_term>
	<mesh_term>Anti-Infective Agents</mesh_term>
	<criteria>Diagnosis CF base following : sweat chloride &gt; 60 mEq/L genotype 2 identifiable mutation consistent CF ; one clinical feature consistent CF Chronically infect P. aeruginosa ( &gt; 50 % respiratory specimen positive P. aeruginosa 24 month prior screen ) Able produce sputum ( expectorate induce ) Able reproducibility perform pulmonary function test Written inform consent provide Sputum culture negative P. aeruginosa density le 10^5 CFU/g screen Sputum culture positive Burkholderia cepacia screen History B. cepacia positive respiratory culture within 24 month prior screen Use antibiotic prescribe principal investigator History allergy ( urticarial rash , diffuse erythroderma , serum sickness ) two group antibiotic ( aminoglycosides , penicillin , cephalosporin , monobactams , macrolides , quinolones ) therapeutic option History anaphylaxis life threaten complication antibiotic six group therapeutic option Post lung transplantation list lung transplantation Pregnancy A septic clinically unstable patient Presence condition abnormality opinion investigator would compromise safety patient quality data</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Pseudomonas aeruginosa</keyword>
	<keyword>biofilm</keyword>
	<keyword>antibiotic susceptibility test</keyword>
	<keyword>pediatrics</keyword>
</DOC>